How do hormones affect tumor DNA in men with breast cancer?

February 14, 2018, The Netherlands Cancer Institute

Breast cancer in men is rare, and men with breast cancer receive the same anti-hormonal therapy as women. Often with effect, but there was no scientific basis for it before now. Cancer researchers led by Wilbert Zwart from the Netherlands Cancer Institute and Oncode Institute are now the first to clarify how hormones affect tumor DNA in men with breast cancer.

Most tumors in men barely differ biologically from those in women. But in tumors that react badly to anti-hormonal , the researchers saw subtle differences between the two sexes. These new insights constitute another major step towards the best personalized treatment for men and women.

The researchers published their findings on February 2 in the scientific journal Nature Communications.

Therapy based on treatment of women

Approximately 100 men per year are diagnosed with breast cancer in the Netherlands, compared to more than 14,000 women. In the vast majority of breast cancers, both in men and women, the tumor is hormone-sensitive. This means that hormones, like estrogen, influence the DNA, causing the tumor to grow and eventually to spread. Anti-hormonal therapy, aimed at blocking the , is therefore also often part of the treatment for men. Often with effect but also with stressful side effects. However, there was not yet a scientific basis for giving men the same treatment as women. The researchers, led by Wilbert Zwart, have now mapped the hormonal function over the entire tumor DNA for the first time and compared men and women.

The first conclusion was that by far most of the breast tumors in men and women are barely distinguishable from each other. This provides a scientific basis for the current practice of giving men and women the same anti-hormonal therapy.

But as with women with hormone-sensitive , there are also men whose still comes back despite the treatment. This group is therefore likely to benefit from a different or supplementary approach. And it is precisely in this group of men that the DNA profiles of the tumor appear to be gender-specific.

Wilbert Zwart: "We had already seen that very specific patterns in women are predictive of the course of the disease. In patients with a less favorable course of the disease, other sites of the DNA are active under the influence of hormones. That says something about the therapy sensitivity of each individual and this knowledge is essential when looking for a personalized therapy. In men, we also see specific patterns that are different than in . If we are to work towards a personalized for men, the selection of medicines may, therefore, have to be slightly different. But a lot of research is still needed for this."

Explore further: Breast cancer treatment link to chronic disease

More information: Tesa M. Severson et al. Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer, Nature Communications (2018). DOI: 10.1038/s41467-018-02856-2

Related Stories

Breast cancer treatment link to chronic disease

January 16, 2018
Women who have undergone hormonal therapy for breast cancer are at increased risk of developing chronic conditions later in life, according to new research.

Pregnancy not dangerous for women who had breast cancer

June 4, 2017
Becoming pregnant after a diagnosis of breast cancer does not raise the risk of the cancer returning, said the largest study of its kind to date, released Saturday at a major cancer conference.

Soybean consumption may be beneficial for some women with breast cancer

June 21, 2017
It can be confusing to know what to eat to lower your risk of breast cancer. Research is mixed, for example, on whether women should avoid soy foods, such as tofu and soybeans, or try to eat more of them. The question is ...

Estrogen plus progestin use linked with increased breast cancer incidence and mortality

March 29, 2013
Estrogen plus progestin use is linked with increased breast cancer incidence. In addition, prognosis is similar for both users and nonusers of combined hormone therapy, suggesting that mortality from breast cancer may be ...

Stopping hormones might help breast cancer to regress

February 28, 2012
As soon as women quit hormone therapy, their rates of new breast cancer decline, supporting the hypothesis that stopping hormones can lead to tumor regression, according to a report e-published in Cancer Epidemiology, Biomarkers, ...

Pregnancy after breast cancer does not increase chance of recurrence

June 5, 2017
Findings from a retrospective study of 1,200 women provide reassurance to breast cancer survivors who are contemplating pregnancy. In the study, women who became pregnant after an early breast cancer diagnosis, including ...

Recommended for you

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.